{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-Enteropancreatic+Neuroendocrine+Tumor&page=2",
    "query": {
      "condition": "Gastro-Enteropancreatic Neuroendocrine Tumor",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-Enteropancreatic+Neuroendocrine+Tumor&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T02:48:32.041Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01204476",
      "title": "Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrin-Producing Neuroendocrine Tumor",
        "Lung Carcinoid Tumor",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Pancreatic Glucagonoma",
        "Pancreatic Insulinoma",
        "Pancreatic Polypeptide Tumor",
        "Paraganglioma",
        "Recurrent Digestive System Neuroendocrine Tumor G1",
        "Recurrent Merkel Cell Carcinoma",
        "Recurrent Pancreatic Neuroendocrine Carcinoma",
        "Regional Digestive System Neuroendocrine Tumor G1",
        "Somatostatin-Producing Neuroendocrine Tumor",
        "Stage III Merkel Cell Carcinoma",
        "Stage IV Merkel Cell Carcinoma",
        "Thyroid Gland Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Octreotide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-15",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204476"
    },
    {
      "nct_id": "NCT03891784",
      "title": "Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Digestive System Neuroendocrine Neoplasm",
        "Digestive System Neuroendocrine Tumor",
        "Foregut Neuroendocrine Tumor",
        "Hindgut Neuroendocrine Tumor",
        "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm",
        "Metastatic Digestive System Neuroendocrine Neoplasm",
        "Midgut Neuroendocrine Tumor",
        "Pancreatic Neuroendocrine Tumor",
        "Refractory Digestive System Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2019-10-31",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03891784"
    },
    {
      "nct_id": "NCT04919226",
      "title": "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT",
          "type": "DRUG"
        },
        {
          "name": "CAPTEM (Capecitabine and Temozolomide)",
          "type": "DRUG"
        },
        {
          "name": "Amino-Acid Solution",
          "type": "OTHER"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ITM Solucin GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 259,
      "start_date": "2021-12-21",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 14,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04919226"
    },
    {
      "nct_id": "NCT02948946",
      "title": "Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "Lung Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "NETest",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2017-01-09",
      "completion_date": "2020-09-15",
      "has_results": false,
      "last_update_posted_date": "2021-08-04",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02948946"
    },
    {
      "nct_id": "NCT06784752",
      "title": "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Somatostatin Receptor Positive (SSTR+)",
        "Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)"
      ],
      "interventions": [
        {
          "name": "[177Lu]Lu-DOTA-TATE",
          "type": "RADIATION"
        },
        {
          "name": "Octreotide LAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 240,
      "start_date": "2025-05-30",
      "completion_date": "2034-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06784752"
    },
    {
      "nct_id": "NCT02611024",
      "title": "Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Glioblastoma",
        "Soft Tissue Sarcoma (Excluding GIST)",
        "Endometrial Carcinoma",
        "Epithelial Ovarian Carcinoma",
        "Mesothelioma",
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "SCLC",
        "Gastric Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Colorectal Carcinoma",
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PharmaMar",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 316,
      "start_date": "2016-05-06",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 4,
      "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611024"
    },
    {
      "nct_id": "NCT04614766",
      "title": "A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastro-enteropancreatic Neuroendocrine Tumor",
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Lutathera",
          "type": "DRUG"
        },
        {
          "name": "Azedra",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Bushnell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09-30",
      "completion_date": "2024-04-23",
      "has_results": false,
      "last_update_posted_date": "2024-04-29",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04614766"
    },
    {
      "nct_id": "NCT01423734",
      "title": "The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastro-enteropancreatic Neuroendocrine Tumor",
        "Secondary Malignant Neoplasm of Liver"
      ],
      "interventions": [
        {
          "name": "magnetic resonance imaging (MRI)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-08-23",
      "completion_date": "2023-01-19",
      "has_results": false,
      "last_update_posted_date": "2023-01-23",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01423734"
    },
    {
      "nct_id": "NCT03017690",
      "title": "Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastroenteropancreatic Neuroendocrine Tumor"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-04-12",
      "completion_date": "2018-05-30",
      "has_results": false,
      "last_update_posted_date": "2018-12-21",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Kenner, Louisiana • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Kenner",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "East Setauket",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03017690"
    },
    {
      "nct_id": "NCT03972488",
      "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastro-enteropancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Lutathera",
          "type": "DRUG"
        },
        {
          "name": "30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)",
          "type": "DRUG"
        },
        {
          "name": "2.5% Lys-Arg sterile amino acid solution",
          "type": "DRUG"
        },
        {
          "name": "High dose 60 mg octreotide long-acting repeatable",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Accelerator Applications",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 226,
      "start_date": "2020-01-08",
      "completion_date": "2027-10-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-07-24T02:48:32.041Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972488"
    }
  ]
}